Patients who underwent transcatheter aortic valve replacement (TAVR) with a valve designed to treat aortic regurgitation had ...

It’s better to be told nothing is wrong than to regret not seeing a medical professional sooner. Here's what you need to know ...

Did you know men and women's heart cells prefer different kinds of fuel? Gender differences are emerging as scientists turn ...

Medtronic (MDT) announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evolut ...

The follow-up brought little surprise, with investigators pleased the risk of death/disabling stroke remained on par with ...

Findings from the first 500 patients treated with the Trilogy system met noninferiority for both safety and efficacy.

Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the EvolutTM ...

Among patients with severe aortic stenosis at low surgical risk, transcatheter aortic valve replacement and surgery conferred ...

Medtronic says its Evolut TAVR shows strong valve performance and durable outcomes at 5 years in low-risk aortic stenosis ...

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evolut™ ...

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evolut� ...